Autonomous Drones & Defense
A defense-tech roll-up scaling revenue fast on a large contracted backlog — funded by heavy share issuance, which is the whole argument.
Personal notes published for reference. Figures are sourced from company filings, releases, and press coverage as of the date above — the interpretation is mine and may be wrong.
The hardest of the four to underwrite here. Management is running an aggressive acquisition strategy — ten acquisitions closed in 2026 alone, with an eleventh (Aran Defense) pending — which demands integration skill on top of operating skill. They have consistently raised guidance, which is a point in their favor, but the track record is short.
Drone warfare and counter-UAS, which has gone from speculative to a procurement priority. Management points to a pipeline of roughly $4.3B across 45+ program submissions, and the $982M Army IDIQ validates relevance to long-term US drone procurement. Modern conflict has made this category structurally larger.
About $1.4–1.5B in cash and short-term investments with minimal debt as of mid-2026 — genuinely funded, though September's acquisition spree put a few hundred million of cash to work on top of a ~$50M/quarter EBITDA burn. The company is still posting substantial losses as expenses scale with the business. Management expects EBITDA positivity during 2026; that has not happened yet.
The strongest of the four criteria for this name. 2025 revenue of $50.7M was up 605% YoY. Q2 2026 revenue hit a record $83.8M against a $68.5M consensus, and full-year guidance was raised repeatedly — from $375M to $390M to more than $525M.
The bull case is the order book. Backlog is what turns a story about drone demand into contracted, visible revenue.
$175M of new orders in Q2, plus a further $105M in Q3 to date. Backlog has climbed from roughly $457M earlier in the year to $613M reported, and ~$757M pro forma once the Q3 acquisitions are included.
Five acquisitions totaling $557M completed in 2026 — Mistral, World View Enterprises, Omnisys, then DZYNE and Cyberhawk in Q3 — expected to contribute roughly $230M of 2026 revenue. DZYNE alone adds a stated $1.5B pipeline and ~$111M of backlog.
Then it kept going. On Sept 14, 2026, Ondas closed GATE Technologies (Israel) and Bron Technologies (Poland) — electronic safe-and-arm and fuzing tech already embedded in dozens of weapon systems, including ~100 loitering-munition configurations — for $105M cash, ~10.7M shares, a $25M working-capital adjustment, ~$22.5M more due within nine months, and up to $185M in stock earn-outs. Management expects the pair to contribute more than $130M of aggregate adjusted EBITDA through 2028. On Sept 23 it added Insignito (acoustic drone detection), Ottopia Defense (remote vehicle control), and CaribouLabs (GPS-denied navigation) for ~$56M plus up to $32M in earn-outs, and it has agreed to buy Aran Defense for ~$33M. The GATE/Bron piece is notable because it's EBITDA-positive — the first deal that pushes toward profitability instead of away from it.
Collaboration with Palantir on AI-enabled defense systems, and the LADOS command-and-control platform debuting alongside a suite of autonomous defense products.
Gross margin actually declined to 43.1% in Q2 from 49.2% in Q1, not held near 50% as the integration pace might suggest. Adjusted EBITDA loss widened nearly 5x quarter-over-quarter, from $10.9M to $50.6M, as operating expenses scaled with the acquisitions. The stock fell 5.4% on the print despite the revenue beat — the market reacting to cost, not demand.
This is the reason the share price hasn't followed the revenue. The growth is real; so is the cost of funding it.
Shares outstanding rose roughly 324% in a single year — diluted average share count around 462M as of March 2026. At the May 2026 annual meeting, shareholders approved raising authorized common stock from 800M to 1.2B shares, with over 50% already issued and nearly 25% reserved for higher-strike warrants. A $229M ESOP-related shelf was filed alongside.
So the company both has diluted heavily and has explicitly created room to keep doing it. That's the bear case in one paragraph.
Shares outstanding were 582.3M on Sept 22, 2026 — up about 26% from the ~462M diluted average in March, in six months. The Sept 23 resale registration (7.8M shares from the World View, Insignito, CaribouLabs, and Ottopia deals) brings no cash to Ondas; it just lets sellers exit. Earn-outs across the new deals are payable mostly in stock, so the share count keeps growing even if Ondas never runs another offering.
On cash specifically: the January $1B raise (~$959M net) is what's funding all of this. Q3 cash outlays — DZYNE, Cyberhawk, $105M+ for GATE/Bron, ~$56M for the September trio, ~$33M for Aran — plus a ~$50M/quarter adjusted EBITDA loss are eating into it fast. No new raise has been announced, and there's still likely several hundred million to a billion left, so it isn't urgent. But at this pace of deals, another raise in 2027 is more likely than not unless EBITDA turns positive. With 1.2B authorized and 582M issued, they have the room to do it.
Revenue growth has outpaced share issuance. On a per-share basis the business is still expanding — and the acquisitions bought with that equity are what produced the backlog. Forward EV/revenue has compressed from ~21x to single digits as estimates caught up. Whether that's cheap or a value trap depends entirely on whether the backlog converts.
Roughly 40–44% of the float has been reported sold short — an unusually crowded bet against the dilution thesis, which makes the stock reflexive in both directions.
Two things: (1) does backlog convert to recognized revenue on schedule, and (2) does share count stabilize now that the cash pile is large. If both happen, the per-share math turns quickly. If issuance continues while conversion slips, the bears are right.
The most direct check on the dilution thesis above: are the same institutions who'd have to absorb the new shares actually buying them, or is the float being sold mostly into retail and short-sellers?
Institutional shares held rose roughly 49% quarter-over-quarter — about 105M shares added — with 383 institutions increasing positions against 88 reducing, and 181 new holders initiating versus 125 exiting entirely. That's a lopsided buy/sell ratio for a name this contested.
BlackRock disclosed a 7.2% passive stake in July 2026. The top 5 holders control roughly 31% of disclosed institutional shares, top 10 about 47% — concentrated, but not dominated by any single fund.
Roughly 40–44% of the float is reported short. Institutions net-buying into that setup while the company keeps issuing shares is a real data point for the bulls — it means the money absorbing the dilution isn't just the company's own ATM desk finding retail buyers.
The market's own reaction to Q2 is the cleanest summary: record revenue and a raised guide, and the stock still fell — because the integration bill showed up faster than the backlog conversion.
If this plays out: ~$5
Record $83.8M revenue and a raised guide still sent the stock down 5.4%, because adjusted EBITDA losses nearly quintupled quarter-over-quarter ($10.9M to $50.6M) and gross margin fell from 49.2% to 43.1% in the same three months. That's the roll-up risk showing up exactly where you'd expect — six-plus acquisitions integrating at once while opex outruns even genuinely strong revenue growth. Layer on the existing 40–44% short interest and last year's 324% dilution, and this needs the backlog to convert cleanly and the margin trend to reverse, with little room for another quarter like Q2's cost overrun.
If this plays out: ~$15
Revenue and backlog keep beating and guidance keeps rising ($525–550M full-year now) — the top-line half of the thesis is still working. What the market re-priced is integration cost discipline, not demand. Institutional ownership climbing (56%+ and still rising) even through this margin scare suggests professional money is underwriting the backlog-conversion story more than the quarterly EBITDA print. Expect the stock to keep trading on the gap between revenue beats and margin trend each quarter until one clearly wins.
If this plays out: ~$22.75
If Q2's margin and EBITDA slippage prove to be a one-quarter integration spike — plausible, given five acquisitions closed inside two quarters — then a company guiding to $525–550M in 2026 revenue on a $757M pro forma backlog looks meaningfully mispriced at $7.72. Analysts already see it that way: Strong Buy consensus, average target above $19, Ladenburg's $22.75 implying nearly triple from here. With 40–44% of the float short against exactly that conversion thesis, one clean quarter — revenue beat and margin improvement together — could move the stock sharply on the squeeze alone.
$7.72 at the Sept 22, 2026 close — down from $9.51 earlier in the month as the acquisition spree and the resale registration landed — against a Strong Buy consensus averaging roughly $19.42–$20.13 (Ladenburg's high at $22.75, raised Aug 17, 2026). That's the widest price-to-target gap on this watchlist — the market is pricing in more execution risk than the sell side is. The scenario targets above are my own rough, directional estimates — not formal price targets — anchored to the sell-side range rather than a full model.
Ten acquisitions closed in 2026, five of them in September alone, across the US, Israel, and Poland, is a lot of moving parts. Roll-ups fail on integration far more often than on demand.
Q2 adjusted loss of $0.19/share missed the $0.10 consensus, gross margin fell to 43.1% from 49.2%, and adjusted EBITDA loss widened nearly 5x to $50.6M. Revenue beats haven't yet translated into the bottom line — if anything, the trend moved the wrong way this quarter.
Revenue is heavily tied to defense procurement timing and budget cycles — lumpy by nature, and politically exposed.